^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Meiyouheng (becotatug vedotin)

    i
    Other names: MRG003, MRG-003, MRG 003
    Company:
    Lepu Med
    Drug class:
    Microtubule inhibitor, EGFR-targeted antibody-drug conjugate
    Related drugs:
    2d
    BLOOM-ON: Becotatug Vedotin Combined With Pucotenlimab for Locally Recurrent Resectable Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=102, Recruiting, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
    New P2 trial
    |
    PD-L1 (Programmed death ligand 1)
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    5d
    A Prospective, Single-arm, Phase II Clinical Trial of Becotatug Vedotin for Injection Combined With Pucotenlimab Injection as a First-line Treatment for Platinum-intolerant Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
    New P2 trial
    |
    IL2 (Interleukin 2)
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    6d
    PRAD2: Becotatug Vedotin Combined With Pucotenlimab ± Radiotherapy as First-Line Treatment for Driver-Gene-Negative, EGFR-Expression-Positive Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=39, Not yet recruiting, Anhui Provincial Cancer Hospital
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    EGFR expression
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    21d
    Study of Becotatug Vedotin Added to Standard Treatment for Advanced Bile Duct Cancer With EGFR Mutations (clinicaltrials.gov)
    P2/3, N=164, Not yet recruiting, Sir Run Run Shaw Hospital
    New P2/3 trial • IO biomarker
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR positive
    |
    cisplatin • gemcitabine • Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    26d
    GATEWAY: Becotatug Vedotin Combined With Pucotenlimab as Neoadjuvant Therapy for Resectable Recurrent Head and Neck Squamous Cell Carcinoma After Progression on Immunotherapy: A Prospective Phase II Study (clinicaltrials.gov)
    P2, N=42, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    27d
    Pucotenlimab Plus Becotatug Vedotin in Perioperative Treatment of Locally Advanced Resectable Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P2, N=80, Not yet recruiting, Lepu Biopharma Co., Ltd.
    New P2 trial
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    28d
    MRG003: Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors (clinicaltrials.gov)
    P1, N=51, Recruiting, Sun Yat-sen University
    New P1 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR positive
    |
    Meiyouheng (becotatug vedotin)
    29d
    MRG003-SACC: A Study of Becotatug Vedotin (MRG003) Combined With Epirubicin as Neoadjuvant Therapy for EGFR-Positive, Unresectable Recurrent Sinonasal Adenoid Cystic Carcinoma (clinicaltrials.gov)
    P2, N=40, Recruiting, Eye & ENT Hospital of Fudan University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression
    |
    epirubicin • Meiyouheng (becotatug vedotin)
    29d
    ADC and SBRT for Recurrent/Metastatic Salivary Gland Carcinoma (clinicaltrials.gov)
    P2, N=40, Not yet recruiting, Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    Meiyouheng (becotatug vedotin) • Jiataile (sacituzumab tirumotecan)
    1m
    Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma (clinicaltrials.gov)
    P2, N=28, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    Loqtorzi (toripalimab-tpzi) • AiRuiKa (camrelizumab) • Meiyouheng (becotatug vedotin)
    2ms
    A Randomized, Open-Label, Exploratory Phase II Clinical Study of MRG003 in Combination with Anti-EGFR Monoclonal Antibody and Pucotenlimab versus Investigator's Choice of Treatment in Patients with EGFR-Positive Esophageal Squamous Cell Carcinoma Who Failed First-Line Standard Therapy (ChiCTR2600121404)
    P=N/A, N=74, Zhejiang Provincial People's Hospital; Zhejiang Provincial People's Hospital
    New trial
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR positive
    |
    Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)
    2ms
    Becotatug Vedotin Combined with Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer (ChiCTR2600121010)
    P2, N=31, Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • MSI (Microsatellite instability) • PD-1 (Programmed cell death 1)
    |
    MSI-H/dMMR • BRAF mutation • RAS wild-type
    |
    Erbitux (cetuximab) • Meiyouheng (becotatug vedotin)